On Thursday, President Donald Trump signed an executive order that instructs federal agencies to begin reclassifying marijuana from a Schedule I drug to Schedule III under the Controlled Substances Act. The White House is pitching the move as a way to widen medical research and expand access to certain cannabidiol (CBD) treatments, while still stopping short of federal legalization. For Chicago residents, the shift could pave the way for easier research at universities and some financial relief for licensed dispensaries, but it will not clear criminal records or legalize interstate sales.
According to The White House, the order directs the attorney general to “complete the rulemaking process” to move marijuana to Schedule III and asks Health and Human Services to develop research methods that use real-world evidence. The same fact sheet outlines a Medicare pilot for certain CBD therapies and urges the administration to work with Congress on standards for hemp-derived cannabinoid products. The order also leans on a 2023 HHS recommendation that acknowledged medical use and pressed federal agencies to move more quickly.
What Rescheduling Means
Moving cannabis to Schedule III would place it among drugs that have accepted medical use and a lower potential for abuse, which puts it in the same category as ketamine and some codeine preparations and lowers hurdles for federally approved research, as reported by The Washington Post. Schedule III status, however, does not legalize recreational sales at the federal level, and it does not automatically erase criminal records tied to past marijuana convictions. Legal experts note that, for now, most day-to-day access and enforcement will remain driven by state law until Congress or federal agencies decide to go further.
Industry And Tax Implications
One immediate practical effect could come via the tax code: rescheduling would likely remove the Internal Revenue Code’s 280E limitation, which currently blocks state-legal cannabis businesses from claiming ordinary business deductions, a change industry analysts say could dramatically improve cash flow, according to Forbes. Markets reacted quickly as investors tried to game out the long-term impact on profit margins and the shape of future federal regulation, per reporting from Reuters. Still, lawyers and policy experts are quick to point out that until the DEA publishes a final rule and the FDA signs off on specific therapies, retail cannabis products will continue to be federally illegal.
Local Impact In Chicago
Illinois has already taken some of the tax sting out for local operators. State lawmakers voted to decouple from federal 280E rules in recent budget legislation, giving Chicago and statewide dispensaries a measure of state-level relief, as noted by the Chicago Sun-Times. The state’s research infrastructure, including programs at the University of Illinois, could also gain from reduced federal barriers to studies involving the plant, according to coverage by Cannabis Science & Technology. Local dispensary owners told reporters they are still digesting the fine print and waiting on agency rulemaking before predicting any concrete shake-up in how they do business.
Advocates And Critics Respond
Civil-liberties organizations are largely greeting the announcement as progress, while warning it is not the end of the story. “Today’s announcement is a significant step toward aligning federal marijuana policy with science,” Nina Patel of the ACLU said in a statement, according to the ACLU. At the same time, opponents in Congress and some public-health advocates argue that the order risks sending mixed messages, especially without parallel moves on clearing records or directing money toward communities most affected by past enforcement.
What Happens Next
The order itself does not instantly change federal law. The Attorney General and the DEA must still run a formal rulemaking process that includes a proposed rule, a public comment period and potentially hearings before a final rule appears in the Federal Register, a timeline legal analysts say could stretch for months, according to McCarter & English. Opponents are also expected to mount legal challenges, which Reuters and other outlets note could drag out any shift in federal enforcement. Even if rescheduling survives both the administrative and courtroom gauntlets, only Congress can fully deschedule marijuana or create a nationwide regulatory framework that lines up the patchwork of state markets.
Chicago residents should brace for a long implementation runway, but they can expect an immediate spike in policy talk, from university research labs to tax accountants’ offices. For local reporting and reaction, see coverage from FOX 32 Chicago. Federal agencies now have to translate an Oval Office order into detailed regulations, and the next few months will reveal whether this turns out to be mostly symbolic or the beginning of a deeper reworking of marijuana’s federal status.
